<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01379547</url>
  </required_header>
  <id_info>
    <org_study_id>201101079RB</org_study_id>
    <nct_id>NCT01379547</nct_id>
  </id_info>
  <brief_title>Procalcitonin to Shorten Antibiotics Duration in ICU Patients</brief_title>
  <acronym>ProShort</acronym>
  <official_title>Procalcitonin to Shorten Antibiotics Duration in ICU Patients- A China, Hong-Kong, Taiwan Multicenter Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Chao Yang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chongqing Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tianjin Medical University General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xinjiang Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Princess Margaret Hospital, Hong Kong</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The trial is aimed to show that implementation of a procalcitonin-guided antibiotics&#xD;
      algorithm may result in shortened antibiotics course in ICU sepsis patients without inferior&#xD;
      outcome as compared to the conventional therapy&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The duration of antibiotic therapy in patients with sepsis is largely empirical. An extended&#xD;
      treatment course for up to two weeks is a common practice for patients with sepsis in the&#xD;
      ICU, despite lack of evidence for this duration of therapy.&#xD;
&#xD;
      Procalcitonin (PCT) is a new biomarker that has high negative predictive value for systemic&#xD;
      bacterial infection. The purpose of this trial is to evaluate whether serial PCT measurements&#xD;
      can shorten antibiotic treatment duration in patients with sepsis in the ICU.&#xD;
&#xD;
      Specific Aims&#xD;
&#xD;
        1. To show that implementation of a procalcitonin-guided antibiotics stewardship algorithm&#xD;
           may result in shortened antibiotics course in ICU sepsis patients&#xD;
&#xD;
        2. To show that implementation of a procalcitonin-guided antibiotics stewardship algorithm&#xD;
           may not result in inferior outcome as compared to conventional therapy&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2011</start_date>
  <completion_date type="Anticipated">June 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Average antibiotics duration</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>28-day mortality rate</measure>
    <time_frame>28 days</time_frame>
    <description>Safety endpoints</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of antibiotics use in both arms</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of ICU stay</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence of fever within 72 hours of antibiotics discontinuation</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>APACHE-II score or SOFA score</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reinfection between 72-hours and 28 days post antibiotics discontinuation</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>90-day all-cause mortality</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>90-day infection related readmission rate</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1700</enrollment>
  <condition>Sepsis</condition>
  <arm_group>
    <arm_group_label>Conventional Treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients who will be randomized to arm 1 will receive antibiotic therapy with a duration based on conventional practice</description>
  </arm_group>
  <arm_group>
    <arm_group_label>procalcitonin-guided antibiotics treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who will be randomized to arm 2 will receive antibiotics therapy with a duration based on procalcitonin-guided algorithm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Procalcitonin guided antibiotics treatment algorithm</intervention_name>
    <description>Patients who will be randomized to arm 2 will receive antibiotics therapy with a duration based on procalcitonin measurement on day 5, 7 and 9.</description>
    <arm_group_label>procalcitonin-guided antibiotics treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Conventional treatment</intervention_name>
    <description>Patients who will be randomized to arm 1 will receive antibiotic therapy with a duration based on conventional practice.</description>
    <arm_group_label>Conventional Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All patients with laboratory- or image-confirmed severe infection at admission or&#xD;
             during stay in ICU will be eligible for inclusion.&#xD;
&#xD;
        Definition of laboratory- or image-confirmed severe infection:&#xD;
&#xD;
          1. Two or more of four Signs of Inflammation&#xD;
&#xD;
               -  Temperature &gt; 38.3℃ or &lt; 36℃&#xD;
&#xD;
               -  Heart rate &gt; 90 beats/min&#xD;
&#xD;
               -  Respiratory rate &gt; 20 breaths/min or PaCO2 &lt; 32 mmHg&#xD;
&#xD;
               -  WBC &gt; 12,000 cells/mm3, &lt; 4000 cells/mm3, or &gt; 10% bands&#xD;
&#xD;
          2. Initial Procalcitonin &gt; 0.5 ng/mL&#xD;
&#xD;
          3. Presence of either laboratory or image evidence of infection&#xD;
&#xD;
        Laboratory evidence:&#xD;
&#xD;
        Sign of inflammation in urine, CSF, ascites, pleural effusion or local abscess&#xD;
&#xD;
        Image evidence:&#xD;
&#xD;
        Compatible findings on Chest X ray、ultrasound、CT、or MR image&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age less than 20 years&#xD;
&#xD;
          -  Known pregnancy&#xD;
&#xD;
          -  Presence of DNR order&#xD;
&#xD;
          -  Expected ICU stay less than 3 days&#xD;
&#xD;
          -  Neutropenia (ANC count &lt; 500/mm3)&#xD;
&#xD;
          -  Specific infections for which long-term antibiotic treatment is strongly recommended:&#xD;
             lung abscess or empyema, bacterial meningitis, osteomyelitis, infective endocarditis,&#xD;
             local abscess, mediastinitis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chien-Chang Lee, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chien-Chang Lee, MD, MSc</last_name>
    <phone>+886-972-651951</phone>
    <email>cclee100@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Critical Care Medicine, The First Affiliated Hospital of Xinjiang Medical University</name>
      <address>
        <city>Urumqi</city>
        <state>Xinjiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Shiangtai Yu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Critical Care Medicine, The 301 People Liberation Army General Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Chin Song, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emergency Department, Beijing Chao-Yang Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chunsheng Li, MD</last_name>
    </contact>
    <investigator>
      <last_name>Chunsheng Li, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emergency Department, Ruijin Hospital, Jiaotong University, School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yiming Lu, MD</last_name>
    </contact>
    <investigator>
      <last_name>Yiming Lu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emergency Department, Xinhua Hospital, Jiaotong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Shuming Pan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Critical Care Medicine, The General Hospital of Tianjin Medical University</name>
      <address>
        <city>Tianjin</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Min Peng, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Pathology, Princess Margaret Hospita</name>
      <address>
        <city>Lai Chi Kok</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Bosco Lam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Emergency, National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Chien-Chang Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ang Yuan, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hsien-Ho Lin, MD ScD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shan-Chewn Chang, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
    <country>Hong Kong</country>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <study_first_submitted>June 21, 2011</study_first_submitted>
  <study_first_submitted_qc>June 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2011</study_first_posted>
  <last_update_submitted>November 26, 2012</last_update_submitted>
  <last_update_submitted_qc>November 26, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 27, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Procalcitonin</keyword>
  <keyword>sepsis</keyword>
  <keyword>ICU</keyword>
  <keyword>antibiotic</keyword>
  <keyword>antibiotic duration</keyword>
  <keyword>Antibiotic treatment duration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

